Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imatinib mesylate, busulfan, fludarabine, ATG and allogeneic stem cell transplantation for chronic myelogenous leukemia.

Next Previous
X
Search
Trial Profile

Imatinib mesylate, busulfan, fludarabine, ATG and allogeneic stem cell transplantation for chronic myelogenous leukemia.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin; Busulfan; Fludarabine; Imatinib; Methotrexate; Tacrolimus
  • Indications Chronic myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Apr 2012 Biomarkers information updated
    • 24 Jan 2012 Actual patient number (42) added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Tacrolimus and methotrexate identified as a components of treatment as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top